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Outcome Reporting in Randomized Trials for
Shoulder Disorders: Literature Review to Inform
the Development of a Core Outcome Set
MATTHEW J. PAGE,1 HSIAOMIN HUANG,2 ARIANNE P. VERHAGEN,3 JOEL J. GAGNIER,2 AND
RACHELLE BUCHBINDER4
Objective. To explore the outcome domains and measurement instruments reported across randomized trials of any
interventions for various shoulder disorders.
Methods. We searched for shoulder trials included in Cochrane reviews published up to Issue 10, 2015, or indexed in
PubMed between 2006 and 2015. Trials were eligible for inclusion if they focused on any intervention for rotator cuff
disease, adhesive capsulitis, shoulder instability, glenohumeral or acromioclavicular osteoarthritis, shoulder disloca-
tion, proximal humeral or humeral head fractures, or unspecified shoulder pain. Two authors independently selected
trials for inclusion and extracted information on the domains and measurement instruments reported, with consensus
discussion among all authors where required.
Results. We included 409 trials, published between 1954 and 2015. Across the trials, we identified 319 different instru-
ments that were classified into 32 domains. Most trials reported a measure of pain (90%), range of motion (78%), and physi-
cal function (71%). The recording of adverse events was reported in only 31% of the trials. Muscle strength was reported in
44% of the trials and imaging outcomes in 21%. Other patient-reported outcome measures, such as global assessment of
treatment success, health-related quality of life, work ability, and psychological functioning, were each reported in ≤15% of
the trials. Most of the domains were reported at similar frequencies across different shoulder disorders.
Conclusion. The domains and measurement instruments reported were widely diverse. Our results provide a founda-
tion for the development of a core outcome set for use in future trials across all shoulder disorders.
INTRODUCTION
Shoulder pain is a significant cause of morbidity and disabil-
ity in the general population (1,2), with an estimated point
prevalence of 7–26% (3). The most common cause of shoul-
der pain is rotator cuff disease, while less common causes
include adhesive capsulitis, glenohumeral osteoarthritis,
and instability or dislocations/fractures resulting from
sports-related injuries in young adults (1,4,5). Although the
causes of shoulder pain vary, there is strong commonality in
end points, with most patients presenting with pain that dis-
rupts sleep patterns, hampers the performance of daily activ-
ities such as dressing and bathing, and negatively affects
recreation and work ability (6,7). Further, the impact of per-
sistent shoulder pain in terms of earnings, missed workdays,
and disability payments is substantial (8,9).
Decisions makers often rely on the results of clinical tri-
als to guide treatment decisions. However, it is not ideal if
the outcomes that are measured have poor or unproven
measurement properties, and if they vary across trials and
hence cannot be compared or synthesized in meta-analyses
(10–12). A promising strategy to reduce variation in out-
come measurement is the development of core outcome
sets (12). This involves defining a set of outcome domains
(i.e., constructs such as pain and function) that should be
measured at a minimum in all trials for a particular
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condition, and then defining the measurement instruments
that must be administered to cover a corresponding domain
(13). Core outcome sets and their recommended measure-
ment instruments have been developed for many muscu-
loskeletal conditions (14), including rheumatoid arthritis
(11,15), low back pain (16), and gout (17), but not yet for
shoulder disorders.
The lack of a core outcome set for shoulder disorders
may have contributed to the wide diversity in measurement
observed in a review of 171 trials of physical therapy inter-
ventions for rotator cuff disease, adhesive capsulitis, and
unspecified shoulder pain (18). However, it is unclear
whether the diversity observed in that review is similar in
trials for other shoulder disorders (e.g., shoulder instability
or glenohumeral osteoarthritis) and for other interventions
(e.g., glucocorticoid injections or tendon repair surgery). It
is possible that other domains that are important to patients
have been measured in trials of interventions other than
physical therapy. Investigating the outcomes measured in a
broader sample of shoulder trials should provide a stronger
foundation for the development of a core outcome set for
use in future trials for all shoulder disorders. The aim of
this review was therefore to expand the previous review of
physical therapy trials by exploring the frequency of out-
come domains and measurement instruments reported
across randomized trials of all interventions for a wider
array of shoulder disorders. We also investigated whether
the reporting of domains varied by disorder.
MATERIALS AND METHODS
Eligibility criteria. The methods for our literature review
were prespecified in a study protocol (19). We included
randomized and quasi-randomized controlled trials
investigating the effects of any intervention for one of the
following shoulder disorders: rotator cuff disease (an um-
brella term to classify disorders of the rotator cuff, includ-
ing subacromial impingement syndrome, rotator cuff
tendinopathy or tendinitis, partial or full rotator cuff tear,
calcific tendinitis, and subacromial bursitis) (20), adhesive
capsulitis, shoulder instability, glenohumeral or acromio-
clavicular osteoarthritis, dislocation of the shoulder, proxi-
mal humeral or humeral head fractures, or unspecified
shoulder pain. Since the criteria used to diagnose shoulder
disorders is not uniform across trials (4,21), we included
trials if they used any of the labels specified above, rather
than basing inclusion on specific diagnostic criteria. We
excluded trials that enrolled patients with systemic inflam-
matory conditions, such as rheumatoid arthritis, hemiplegia
causing secondary shoulder pain, or pain in the shoulder
region as part of a complex myofascial neck/shoulder/arm
pain condition (e.g., complex regional pain syndrome).
Trials were eligible if they compared any active intervention
(e.g., manual therapy, surgery, or glucocorticoid injection) to
placebo, no treatment, or another active intervention. We
only included completed trials that were written and pub-
lished in English.
Search methods. We used 3 approaches to identify trials.
We included all trials examined in the previous review of
domains and instruments used in physical therapy trials
(18). We searched the Cochrane Database of Systematic
Reviews (up to issue 10, 2015) and screened the list of
included studies in all Cochrane reviews of interventions for
shoulder disorders. We also searched PubMed (January 2006
to December 2015) to identify recently published trials
that may not have been included in the Cochrane reviews.
The full Boolean search strategies for both databases are
shown in Supplementary Appendix A (see Supplementary
Appendix A, available on the Arthritis Care & Research web
site at http://onlinelibrary.wiley.com/doi/10.1002/acr.23254/
abstract).
Selection of trials. One of 2 authors (MJP or HH) screened
all titles and abstracts against the eligibility criteria. The
full text of articles assumed to be eligible, or with
uncertain eligibility, were retrieved and screened indepen-
dently by both authors. Discrepancies were resolved through
discussion.
Data extraction and management. Data from Cochrane
reviews and the PubMed-indexed trials were extracted by 1
author (either MJP or HH) and verified by the second auther.
Discrepancies were resolved through discussion until
consensus was reached. Data were extracted from the
characteristics of included studies table of each Cochrane
review (which includes detailed information on the domains
and instruments reported in each trial), or from the full-text
report of each PubMed-indexed trial. We recorded for each
trial the year of publication, diagnostic label used, sample
size, intervention under investigation (for head-to-head trials,
we recorded the first intervention mentioned in the trial
objectives), and all outcome measurement instruments
described either in the Methods or Results section of the
article. As defined by the Outcome Measures in Rheu-
matology (OMERACT) filter 2.0, a measurement instrument
Significance & Innovations
• Across 409 trials for various shoulder disorders
(e.g., rotator cuff disease, adhesive capsulitis,
shoulder instability, and proximal humeral/hu-
meral head fracture), we identified 319 measure-
ment instruments that were classified into 32
domains. This diversity is so extensive that the
ability to compare and synthesize the results of
shoulder trials is severely hampered.
• The most common domains, consistently measured
across all trials, were pain (90%), range of motion
(78%), and physical function (71%), while other
patient-reported outcome measures such as global
assessment of treatment success, health-related
quality of life, work ability, and psychological func-
tioning, were each reported in ≤15% of the trials.
• Most of the domains were reported at similar fre-
quencies across the different shoulder disorders,
which suggests that it would be appropriate to
develop a single core outcome set for all shoulder
disorders.
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could be a single question, a questionnaire, a score obtained
through physical examination, a laboratory measurement, or
a score obtained through observation of an image (13). If
results of trials had been reported in multiple journal articles,
we extracted data from the trial as a unit by incor-
porating information from all corresponding articles. Once
data extraction was complete, the data set was combined
with the data set used in the previous review of physical
therapy trials (18).
Classification of outcome measurement instruments into
domains. One of 2 authors (MJP or HH) classified each
reported outcome measurement instrument under the
domain that its developers originally designed it to
address. If the instrument was unknown to the authors,
classification was guided by retrieving the article that first
described the content or measurement properties of the
instrument. One author (MJP) then classified each domain
under 1 of the 4 areas of the OMERACT filter 2.0 (life
impact [e.g., quality of life, activities of daily living],
resource use [e.g., health care visits and associated costs],
pathophysiologic manifestations [e.g., changes in body
function and structure that accompany a condition], and
mortality) (13). The same author classified domains using
the International Classification of Functioning, Disability,
and Health (ICF) conceptual model developed by the
World Health Organization (22). Two authors with
expertise in shoulder-specific measurement instruments
(JJG and RB) verified all classifications for appropriateness.
Statistical analysis. We summarized results using fre-
quencies and percentages for binary outcomes and medians
and interquartile ranges (IQRs) for continuous outcomes.
The frequency of outcome domains was calculated for the
complete set of trials and for trials subgrouped by shoulder
disorder (namely, rotator cuff disease, adhesive capsulitis,
shoulder instability, glenohumeral/acromioclavicular osteo-
arthritis, shoulder instability, and fractures/dislocations;
fractures and dislocations were grouped together because of
their similar etiology). Analyses were undertaken using
Stata, version 13 (23).
RESULTS
The inclusion criteria were met by 121 trials included in
18 Cochrane reviews, and 117 PubMed-indexed trials,
which were combined with the 171 physical therapy trials
evaluated in the previous review (18). Therefore, we
Figure 1. Flow diagram of the process of identifying and screening the trials included in this review. SRs = systematic reviews.
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evaluated 409 unique trials in total (Figure 1). The trials
were published between 1954 and 2015 (Table 1). Most
trials were for rotator cuff disease (186/409, 45%), fol-
lowed by adhesive capsulitis (97/409, 24%), and shoulder
instability or proximal humeral/humeral head fracture
(both in 31/409 trials [8%]). There were 18 types of inter-
ventions under investigation across the trials. Manual
therapy or exercise (delivered alone or in combination)
was the most common intervention (140/409, 34%), fol-
lowed by surgery (104/409, 25%), electrotherapy modali-
ties (such as therapeutic ultrasound; 65/409, 16%), and
glucocorticoid injection (45/409, 11%). The trials
included a median of 50 (IQR 38–75) participants.
Across the trials, we identified 319 different instruments
classified into 32 domains. The majority of the trials includ-
ed a measure of pain (368/409, 90%), range of motion (320/
409, 78%), and physical function (289/409, 71%). The mea-
surement of adverse events (serious or nonserious) was
reported in only 126/409 trials (31%). A measure of muscle
strength was reported in 178/409 trials (44%), and a radio-
graphic outcome (i.e., any measure of the structure of the
bones/joints/tendons evaluated via imaging) was reported
in 86/409 (21%) trials. Other domains (e.g., global assess-
ment of treatment success, health-related quality of life,
work ability, health care services use, or psychological
functioning) were each reported in ≤15% of the trials.
Assessment of the number of deaths was reported in only
13/409 trials (3%).
Using the OMERACT filter 2.0, 11 domains were classi-
fied under the life impact area (including pain, physical
function, and global assessment of treatment success)
(Table 2). Fifteen domains were classified under the patho-
physiologic manifestations area (including range of motion,
muscle strength, and radiographic outcomes) (Table 3).
Four domains were classified under the resource use area
(e.g., health care services or work productivity) (Table 4).
The numbers of deaths and adverse events do not fall under
these three areas, but make up the last 2 domains. Using
the ICF conceptual model, all of the domains shown in
Table 2 fall under activities and participation, while all of
the domains shown in Table 3 fall under body functions
and body structures.
Table 1. Characteristics of the 409 included trials
Characteristic No. (%)
Year of publication
1954–2001 90 (22)
2002–2006 55 (13)
2007–2010 103 (25)
2011–2015 161 (39)
Shoulder disorder
Rotator cuff disease 186 (45)
Adhesive capsulitis (frozen shoulder) 97 (24)
Shoulder instability 31 (8)
Proximal humeral or humeral head
fracture
31 (8)
Unspecified shoulder pain 30 (7)
Dislocation of the shoulder 17 (4)
Glenohumeral or acromioclavicular
osteoarthritis
16 (4)
Mixed (some with rotator cuff disease,
others with instability)
1 (0.2)
Intervention under investigation
Manual therapy or exercise (or both
delivered in combination)
140 (34)
Surgery (e.g., tendon repair surgery for
rotator cuff tear)
104 (25)
Electrotherapy modalities (e.g., therapeutic
ultrasound, laser therapy)
65 (16)
Glucocorticoid injection 45 (11)
Platelet-rich plasma therapies 11 (3)
Acupuncture 8 (2)
Oral glucocorticoids 8 (2)
Intraarticular lignocaine 5 (1)
Arthrographic distension of the
glenohumeral joint with
glucocorticoid and saline
4 (1)
Sodium hyaluronate injection 4 (1)
Topical glyceryl trinitrate 3 (1)
Botulinum toxin 3 (1)
Extracorporeal shockwave therapy 3 (1)
Continuous interscalene brachial plexus
block
2 (0.5)
Manipulation under anesthesia 1 (0.2)
Needling fragmentation irrigation 1 (0.2)
Radiotherapy 1 (0.2)
Suprascapular nerve block 1 (0.2)
Table 2. Outcome Measures in Rheumatology life impact (International Classification of Functioning, Disability, and
Health activities and participation) outcome domains in the 409 included trials
Domain (definition/examples) No. (%)
No.
instruments
Pain (how much a person’s shoulder hurts overall, during or following activity, at night, etc.) 368 (90) 47
Physical functioning (ability to carry out physical activities of daily living, such as dressing or bathing) 289 (71) 49
Global assessment of treatment success (person’s assessment of their recovery or degree of
improvement)
62 (15) 9
Health-related quality of life (physical, psychological, and social domains of health) 62 (15) 12
Satisfaction with treatment services (person’s satisfaction with care received) 61 (15) 6
Social functioning (ability to engage in normal social activities with family/friends) 29 (7) 2
Work ability (ability to meet physical or psychological demands of work) 24 (6) 4
Recreation and leisure activity (ability to engage in recreational or leisure activities, including sports) 22 (5) 7
Psychological functioning (depression, anxiety) 18 (4) 10
Severity of the main complaint (how much a person’s main concern, be it pain or disability,
bothers them)
5 (1) 1
Sleep functioning (impact of disorder on onset, maintenance, quality, and amount of sleep) 2 (0.5) 2
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A wide range of instruments was used to measure the
same outcome across the included trials (see Supplemen-
tary Table 1, available on the Arthritis Care & Researchweb
site at http://onlinelibrary.wiley.com/doi/10.1002/acr.23254/
abstract). Pain was measured by 47 different instruments,
which varied in terms of the type of pain addressed (e.g.,
night pain intensity and pain at rest or with activity),
descriptor for the maximum score on the scale (e.g., “intol-
erable pain” or “worst pain imaginable”), and period of
interest (e.g., pain within the last 24 hours versus pain
within the last week). The most common was overall pain
measured using a visual analog scale (VAS) (174/409 trials
[43%]). There were 49 different measures of physical func-
tion, and of these, the Constant-Murley score (24) was used
most often (128/409 trials [31%]), followed by the Shoulder
Pain and Disability Index (25) (49/409 trials [12%]). Nearly
all (44/49 [90%]) of these instruments were patient-
reported outcome measures (PROMs), and 4 instruments
(including the Constant-Murley score and the American
Shoulder and Elbow Surgeons score) include physician-
observed measures of functional impairment. Radiography
was used to measure various structural outcomes, such as
rotator cuff repair integrity, subluxation (partial disloca-
tion), acromiohumeral distance, and presence of calcific
deposits. Of the measures of muscle strength, most were
performed using a dynamometer to measure isokinetic or
isometric strength in different positions (e.g., strength in
flexion or strength in abduction). Range of motion was mea-
sured using either a goniometer or tape measure, although
there was variation in the type of movements assessed (e.g.,
flexion, extension, or abduction), the number of movements
assessed, and whether movements were active or passive.
Other domains were assessed by a median of 3 instruments
(range 1–12).
Most domains (24/32, 75%), including pain, physical
function, and range of motion, were reported at similar
Table 3. Outcome Measures in Rheumatology pathophysiologic manifestations (International Classification of
Functioning, Disability, and Health body functions and structures) outcome domains in the 409 included trials
Domain (definition/examples) No. (%)
No.
instruments
Range of motion (distance and direction that the shoulder is able to move, for example, in flexion
or abduction, either when initiated by the person or guided by the care provider)
320 (78) 25
Muscle strength (force generated by the contraction of a shoulder muscle) 178 (44) 38
Radiographic outcomes (any measure of the structure of the bones/joints/tendons measured via
imaging, such as rotator cuff repair integrity, acromiohumeral distance)
86 (21) 46
Shoulder instability (loosening of connective tissue surrounding the shoulder joint, which can
sometimes result in the head of the upper arm bone slipping out of the shoulder socket)
25 (6) 3
Failure of surgery (inability of the surgery to correct a specific structural problem, such as
malunion of a fracture after surgery)
24 (6) 8
Testing positive on specific tests during physical examination (e.g., painful arc test for rotator cuff
disease, relocation test for shoulder instability)
21 (5) 8
Surgical process outcomes (measures of the implementation of a surgical intervention) 20 (5) 7
Pain on palpation (pain following touch of any muscle, tendon, and bony prominences of the
shoulder region)
7 (2) 1
Scapular dysfunction (problems with rotating the scapular or poor motor control of the scapular) 7 (2) 8
Proprioception of the shoulder (person’s sense of position and movement of the shoulder) 5 (1) 2
Muscle tone (slight tension or firmness present in resting muscles of the shoulder) 4 (1) 7
Shoulder posture (position in which shoulder is held upright against gravity while standing,
sitting, or lying down)
2 (0.5) 1
Weakness on movement (person’s sense that more effort than normal is required to move the
shoulder)
1 (0.2) 1
Shoulder swelling (abnormal enlargement caused by accumulation of fluid in the shoulder joint) 1 (0.2) 1
Hemodynamic variables (any measure of blood flow, such as blood pressure or heart rate) 1 (0.2) 1
Table 4. Outcome Measures in Rheumatology resource use outcome domains in the 409 included trials
Domain (definition/examples) No. (%)
No.
instruments
Requiring reoperation or revision surgery (use of additional surgical procedures following failure of
the first attempt)
35 (9) 1
Health care services (health care visits, laboratory tests, imaging, days of admission to a hospital,
medications)
29 (7) 4
Non–health care services (visits to professionals of alternative medicine, over-the-counter
medications, patient’s time and travel expenses)
29 (7) 4
Work productivity (economic impact of absenteeism due to shoulder disorder) 23 (6) 2
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frequencies across the different shoulder disorders (Fig-
ure 2 and Supplementary Table 2, available on the Arthritis
Care & Research web site at http://onlinelibrary.wiley.c
om/doi/10.1002/acr.23254/abstract). Exceptions to this
included the following: trials for adhesive capsulitis less
frequently reported a measure of muscle strength; trials for
shoulder fracture/dislocation more frequently reported a
measure of adverse events, number of deaths, radiographic
outcomes, requiring reoperation and failure of surgery; tri-
als for osteoarthritis more frequently included a measure of
radiographic outcomes; and trials for shoulder instability
more frequently included a measure of instability and
recreation/leisure activities.
DISCUSSION
We found that the outcome domains and measurement
instruments in trials of many different interventions for
several shoulder disorders are widely diverse. Across the
trials we identified 319 different instruments, which were
classified into 32 domains. Most trials included a measure
of pain (90%), range of motion (78%), and physical func-
tion (71%). Measurement of muscle strength was reported
in 44% of the trials, and measurement of radiographic
outcomes was reported in 21% of the trials. Other domains,
particularly PROMs such as global assessment of treatment
success, health-related quality of life, work ability, and psy-
chological functioning, were each reported in ≤15% of the
trials. There were 47 different measurement instruments
for pain and 49 for function across the trials; nearly all of
the latter were PROMs. Most domains were reported at a
similar frequency across the different shoulder disorders.
Measurement of adverse events was reported in only 31%
of the trials.
A strength of our study is the inclusion of trials investi-
gating a diverse set of interventions for an array of shoul-
der disorders, which enhances the generalizability of the
findings. In addition, the majority of our sample of trials
was identified from published Cochrane reviews, each of
which used a comprehensive search strategy and methods
to minimize error in trial selection. However, some limita-
tions need to be considered. Selective reporting of only
the positive/statistically significant outcomes is common
in clinical trials (26), and so by relying on what was
reported rather than asking trialists about any nonreported
domains and instruments, we may have underestimated
the frequency of outcome domains and instruments that
were actually measured. Also, rather than updating the
Figure 2. Percentage of trials measuring the most commonly measured domains, subgrouped by shoulder disorder. HRQoL = health-
related quality of life; RCD = rotator cuff disease; AC = adhesive capsulitis; OA = osteoarthritis.
Shoulder Disorders Outcome Reporting 257
searches of each Cochrane review on a shoulder disorder,
we searched PubMed only for shoulder trials indexed in
the last 10 years. Therefore, it is likely that we have not
identified all published trials for shoulder disorders. How-
ever, we are not aware of any evidence that outcomes mea-
sured in trials included in Cochrane reviews or indexed in
PubMed differ from those in trials indexed elsewhere.
Therefore, we do not believe our findings are unrepresen-
tative of all shoulder trials.
This review extends the findings of a previous review of
physical therapy trials (18) in several ways. We included a
much larger sample of trials (409 versus 171) addressing a
more comprehensive set of questions. This led to the identi-
fication of 12 domains that were not previously recorded,
namely the number of deaths, radiographic outcomes,
shoulder instability, failure of surgery, surgical process out-
comes, requiring reoperation or revision surgery, satisfac-
tion with treatment services, social functioning, recreation
or leisure activity, sleep functioning, nonuse of health care
services, and hemodynamic variables. We also identified a
larger number of measurement instruments for the same
domain (for example, 35 pain instruments and 29 function
instruments were noted in the previous review, compared
with 47 and 49, respectively, in the current sample). Using
the OMERACT filter 2.0 (13) and ICF framework (22) to
classify domains, we found that slightly more (15/32 versus
11/32) of the domains used in shoulder trials were mea-
sures of changes in body function and structure that accom-
pany the disorder (i.e., pathophysiologic manifestations in
OMERACT terms or body functions and structures in the
ICF conceptual model), rather than measures of perfor-
mance of activities of daily living, work, and recreation/lei-
sure (life impact in OMERACT terms or activities and
participation in the ICF conceptual model). Finally, the
measurement of adverse events was reported only slightly
more often in the current sample (31% versus 27%), sug-
gesting that trials of interventions other than physical ther-
apy are not immune from poor harms reporting.
Most of the domains we identified (75%) were measured
at similar frequencies across all of the included shoulder
disorders (including pain, physical function, and range of
motion). Because of this, we think it would be appropriate
to develop a single core outcome set for all shoulder disor-
ders, rather than developing different sets for different dis-
orders (e.g., one for rotator cuff disease and a different one
for adhesive capsulitis). A single core outcome set would
not preclude trialists from measuring other domains that
might be especially relevant in the context of the particular
trial (13,27). For example, a trial of surgical repair of rotator
cuff tears may use imaging to assess the integrity of the
repair, whereas a trial of an intervention designed to
improve shoulder posture may measure improvement in
posture, and a trial for shoulder instability in young ath-
letes may measure the time to return to sport. However, we
recognize that the decision to create a single core outcome
set for all shoulder disorders requires consideration from
various stakeholders, the most important of which are the
patients, who can help ensure that the core outcome set suf-
ficiently captures the experience of their condition (28).
Government sponsorship of initiatives such as the
Patient-Centered Outcomes Research Institute indicates that
policymakers have a strong desire for PROMs to be collected
in clinical trials (29). Previous shoulder trials have done
well at measuring patient-reported pain, but infrequently
measured other potentially important PROMs, such as glo-
bal assessment of treatment success, health-related quality
of life, work ability, sleep quality, and psychological func-
tioning. Also, while many patient-reported measures of
physical functioning were identified across the trials, the
most commonly used one, the Constant-Murley score,
which was used in 31% of the trials, includes physician-
rated components to measure range of motion and strength
(impairment measures). It is unclear whether trialists
believe that pain is the only PROM that should be measured
in shoulder trials, have concerns about the measurement
instruments available to measure other PROMs, or believe
that non-PROMs such as range of motion (measured using a
goniometer) or radiographic outcomes are more valid and
reliable. Many studies have found that PROMs do not corre-
late well with objectively measured outcomes in people
with shoulder disorders (30–33), yet provide valuable
insight into the overall burden that a health condition
places on an individual (34). In the future, it would be valu-
able to ask different stakeholders for their opinion on the
relative value of PROMs and non-PROMs for shoulder disor-
ders, and to consider which PROMs are the most essential
to include in a core outcome set for shoulder disorders.
Additional research is needed before we can recommend a
core outcome set for shoulder disorders, and the results of
this literature review should therefore be considered prelimi-
nary only. It is possible that the outcome domains previously
measured in shoulder trials do not fully represent the lived
experience of people with shoulder disorders. Other domains
that have never been measured in past trials may exist, and
could be elicited from patients using qualitative methods,
such as focus groups and interviews (35). Further, a plethora
of instruments have been collated in this review, but we have
not yet evaluated their measurement properties, including
construct validity, test–retest reliability, and responsiveness.
The instruments most frequently used in past trials may not
necessarily be the best at reliably detecting changes in symp-
toms/function over time. A systematic review of the measure-
ment properties of instruments for shoulder disorders will
help to determine which are most fit for this purpose.
In conclusion, there is a wide variety of domains and
instruments being used in trials for various shoulder disor-
ders. The most common domains, consistently measured
across all trials, were pain, range of motion, and physical
function. We will use the results of this review to inform an
international Delphi study to select core domains, and then
review the measurement properties of applicable instru-
ments. Such research will ultimately lead to the creation of
a core set of domains and recommended instruments for
use in trials for shoulder disorders, and the endorsement of
OMERACT will be sought.
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